Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectory of liver-related events following incident cardiovascular disease in MASLD: A 15-year population-based cohort study.

Metabolism: clinical and experimental·2026
Same author

Delphi survey to explore core curriculum for training the next-generation of hepatologists<sup>☆</sup>.

JHEP reports : innovation in hepatology·2026
Same author

Burden and Regional Disparities of MASH-Related Liver Cancer in the Asia-Pacific Region From 1990 to 2023.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026
Same author

MASLD prevalence, incidence and global aspects.

Diabetologia·2026
Same author

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The lancet. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Jan 17, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

714

Biomarker Discovery for Metabolic Dysfunction-associated Steatotic Liver Disease Utilizing Mendelian Randomization,

Gong Feng1, Giovanni Targher2,3, Christopher D Byrne4

  • 1Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Journal of Clinical and Translational Hepatology
|September 15, 2025
PubMed
Summary

This study identifies causal molecular and clinical biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD). Serum total protein (STP) mediates HLA-A effects and predicts mortality, while CNPY4 and ENTPD6 link to liver cancer survival.

Keywords:
Causal biomarkersMachine learningMediation analysisMendelian randomizationMetabolic dysfunction-associated fatty liver diseaseNon-invasive diagnosisPrognosisProteomics

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.6K

Related Experiment Videos

Last Updated: Jan 17, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

714
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.6K

Area of Science:

  • Hepatology
  • Biomarker Discovery
  • Genetics

Background:

  • Causal biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) are not well-defined.
  • Understanding these biomarkers is crucial for diagnosis and prognosis.

Purpose of the Study:

  • Identify causal molecular and clinical biomarkers for MASLD.
  • Evaluate their diagnostic and prognostic significance.

Main Methods:

  • Mendelian randomization analysis of proteomics and clinical data.
  • Mediation analysis to explore biomarker interactions.
  • External validation and machine learning model development for diagnosis.
  • Prognostic evaluation of identified biomarkers.

Main Results:

  • Six molecular (e.g., CNPY4, ENTPD6, HLA-A) and eight clinical biomarkers (e.g., serum total protein - STP) causally linked to MASLD.
  • STP partially mediated HLA-A's effect on MASLD and was validated externally.
  • A machine learning model achieved high diagnostic accuracy (AUC=0.941).
  • CNPY4 and ENTPD6 correlated with hepatocellular carcinoma development and survival.
  • Low STP predicted all-cause mortality.

Conclusions:

  • Identified novel causal molecular and clinical biomarkers for MASLD.
  • STP plays a mediating role and has prognostic value for mortality.
  • Molecular biomarkers CNPY4 and ENTPD6 are associated with liver cancer outcomes.